Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IXIARO booster immunogenicity in elderly versus young adults
2016-002894-36Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Nov 2017
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of Japanese encephalitis inactivated vaccine in Japanese encephalitis (JE) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Fold-increase of JEV-antibody titre from pre-booster to 6 weeks after booster. Started Nov 2017; status: completed.
02
Drugs
Japanese encephalitis inactivated vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on 2016-002894-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002894-36.